Figure 1
From: CD95 maintains stem cell-like and non-classical EMT programs in primary human glioblastoma cells
CD95 is a prognostic biomarker in GBM patients and linked to stem cell and EMT gene expression patterns. (a) CD95 expression in TCGA GBM samples compared with unmatched non-tumor control tissue (Wilcoxon test). (b) CD95 expression compared between distinct GBM subtypes in the TCGA data set (Wilcoxon test with Holm correction). (c) Overall survival in TCGA GBM patients stratified according to CD95 expression. (d) Progression-free survival in TCGA GBM patients stratified according to CD95 expression (log-rank test). (e) Overall survival in TCGA GBM patients grouped by subtype (log-rank test). (f) TCGA data set genes ranked according to signal-to-noise ratios for CD95high/CD95int versus CD95low expression groups. (positive values (red): higher expression in the CD95high/int group; negative values (blue): higher expression in the CD95low group). (g) GSEA for enrichment of an adult NSC gene signature in the ranked TCGA gene data set. (h) GSEA for enrichment of an EMT gene signature in the ranked TCGA gene data set
